Back

Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer

Forjaz, A.; Mojdeganlou, H.; Valentin, A.; Wetzel, M.; Lvovs, D.; Deshpande, A.; Shin, S. M.; Piya, S.; Rajapakshe, K. I.; Guerrero, P. A.; Pedro, B. A.; Sidiropoulos, D. N.; Wu, P.-H.; Bernard Pagan, V.; Demystifying Pancreatic Cancer Therapies TeamLab, ; Wirtz, D.; Fertig, E. J.; Kagohara, L. T.; Ho, W. J.; Kiemen, A. L.; Wood, L. D.

2026-03-05 cancer biology
10.64898/2026.03.03.709150 bioRxiv
Show abstract

Resistance to systemic therapy is a major unmet challenge in pancreatic cancer. To identify potential mechanisms of resistance, we developed a novel 3D pipeline in clinical samples that uses deep learning to classify sensitive and persistent tumor cell populations based on morphological features, enabling subsequent molecular characterization of intratumoral heterogeneity. We applied this automated 3D pipeline to a cohort of human pancreatic cancer samples treated with neoadjuvant chemotherapy, identifying heterogeneity in response to therapy both between and within tumors. Application of spatial proteomics to these sensitive and persistent regions identified enhanced epithelial-to-mesenchymal transition and non-classical cell states in persistent cells, confirming our morphological classification. Integration of spatial transcriptomics in multiple pancreatic cancer cohorts associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy. Our validated 3D multi-omic pipeline is now poised for application to clinical trials, enabling discovery of resistance mechanisms and design of new therapeutic combinations to circumvent resistance. Statement of significanceWe developed a novel 3D multi-omic pipeline to identify mechanisms of resistance to chemotherapy in clinical samples. This approach associated fibroblast-cancer crosstalk via syndecans with resistance to cytotoxic therapy and is poised for broader application in neoadjuvant clinical trials.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 2%
23.4%
2
Cancer Cell
38 papers in training set
Top 0.1%
13.0%
3
Cell Reports Medicine
140 papers in training set
Top 0.8%
4.5%
4
EMBO Molecular Medicine
85 papers in training set
Top 0.3%
4.5%
5
Cancer Discovery
61 papers in training set
Top 0.5%
3.7%
6
Molecular & Cellular Proteomics
158 papers in training set
Top 0.8%
2.7%
50% of probability mass above
7
Cancer Research
116 papers in training set
Top 1%
2.7%
8
Science Advances
1098 papers in training set
Top 11%
2.4%
9
Genome Medicine
154 papers in training set
Top 4%
2.0%
10
Cell Metabolism
49 papers in training set
Top 0.8%
2.0%
11
Advanced Science
249 papers in training set
Top 9%
2.0%
12
Cell Systems
167 papers in training set
Top 7%
1.7%
13
Molecular Systems Biology
142 papers in training set
Top 0.6%
1.7%
14
eLife
5422 papers in training set
Top 41%
1.7%
15
Nature Genetics
240 papers in training set
Top 5%
1.4%
16
Clinical Cancer Research
58 papers in training set
Top 1%
1.1%
17
Cell
370 papers in training set
Top 14%
1.1%
18
JCI Insight
241 papers in training set
Top 5%
1.0%
19
Cancer Research Communications
46 papers in training set
Top 0.8%
1.0%
20
Nature Cancer
35 papers in training set
Top 1%
1.0%
21
Developmental Cell
168 papers in training set
Top 10%
0.9%
22
Cell Reports
1338 papers in training set
Top 30%
0.9%
23
Communications Biology
886 papers in training set
Top 18%
0.9%
24
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 40%
0.9%
25
iScience
1063 papers in training set
Top 28%
0.8%
26
PLOS Computational Biology
1633 papers in training set
Top 24%
0.8%
27
Genome Biology
555 papers in training set
Top 7%
0.7%
28
eBioMedicine
130 papers in training set
Top 4%
0.7%
29
npj Systems Biology and Applications
99 papers in training set
Top 2%
0.7%
30
The Journal of Pathology
22 papers in training set
Top 0.5%
0.7%